Trial Profile
A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) Short title: LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE (LATITUDE)-TIMI 60
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary)
- Indications Acute coronary syndromes
- Focus Registrational; Therapeutic Use
- Acronyms LATITUDE-TIMI 60
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 28 May 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
- 08 May 2019 This trial has been completed in Estonia, according to European Clinical Trials Database.
- 16 Nov 2016 Results of exploratory analysis (n=865) presented at the 89th Annual Scientific Sessions of the American Heart Association